Tetrodotoxin
In clinical developmentRecent clinical, regulatory, research and industry developments relating to this drug.
A human in vitro neuronal model for studying homeostatic plasticity at the network level.
Binocular impulse blockade prevents the formation of ocular dominance columns in cat visual cortex.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes4
Journals, researchers & institutions
- The Journal of neuroscience : the official journal of the Society for Neuroscience2
- Stem cell reports1
- Chattopadhyaya B1
- Ciptasari U1
- Di Cristo G1
- Esteve-Codina A1
- Franke B1
- Frega M1
- Harris WA1
- Higashiyama H1
- Centre for Genomic Regulation1
- Cold Spring Harbor Laboratory1
- Department of Clinical Neurophysiology1
- Radboud University Medical Center1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Frequently co-studied with Tetrodotoxin in the research literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials